Acurx secures antibiotic patents in Japan and Mexico
U.S.-based biopharma gains intellectual property protection for two antibiotic candidates in key markets, expanding commercialization potential.
Acurx Pharmaceuticals said it has been granted patents for two of its antibiotic candidates in Japan and Mexico, reinforcing its intellectual property portfolio in global markets.
The patents cover Acurx’s lead drug candidate, ibezapolstat, a novel antibiotic being developed for the treatment of Clostridioides difficile infections, and a second candidate, ACX-362E, designed to target bacterial infections. The approvals in Japan and Mexico expand the company’s patent protection beyond its existing U.S. and European patents, the company said.
Acurx, a U.S.-based biopharmaceutical firm, has been advancing ibezapolstat through clinical trials, with Phase 3 studies underway for C. difficile infections. The drug is positioned as a potential first-in-class treatment, targeting the bacteria responsible for the infection through a novel mechanism of action. ACX-362E is in earlier-stage development for broader bacterial indications.
The patents in Japan and Mexico provide commercial exclusivity in those markets, which could facilitate partnerships or licensing agreements to accelerate market access. Acurx has previously highlighted its strategy to leverage its patent portfolio to secure collaborations with larger pharmaceutical companies.
Financial terms related to the patents were not disclosed. Acurx trades on the Nasdaq under the ticker ACXP.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →